Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Tuesday, September 14, 2010

abstract: 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

"...Altogether, our data show that 6TG efficiently kills BRCA2-defective tumors and suggest that 6TG may be effective in the treatment of advanced tumors that have developed resistance to PARP inhibitors or platinum-based chemotherapy."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.